NUR 521 Advanced Pharmacology – The University of Alabama – Capstone College of Nursing (2024) – Anticoagulant Compare and Contrast Chart Summary

The University of Alabama
Capstone College of Nursing
NUR 521 Advanced Pharmacology
Anticoagulant Compare and Contrast Chart

Instructions: Complete this chart while you are listening to the lecture or as a review after the lecture. This is a
learning activity to help you review and organize the content presented in the lecture. This activity will not be
graded and will not be submitted in the course.

Drug Heparin Lovenox Warfarin Xarelto Plavix
Mechanism of  Helps  Similar MOA as  Suppresses  Selective  Effects much like
Action antithrombin heparin, but coagulation by inhibition of ASA
inactivate clotting mostly inactivates decreasing factor Xa  Blocks P2Y12
factors thrombin factor Xa production of 4  Binds directly ADP receptors on
and factor Xa. vitamin K with the active Plts  preventing
 Ultimately dependent center of factor ADP stimulated
suppresses clotting factors Xa  Plts aggregation
formation of fibrin (VII, IX, X, and inhibiting  Anti Plt effects
prothrombin) production of last the lide cycle
 Inhibits an thrombin of the Plt.
enzyme needed to
convert vit. K to
its active form.

Use  Prophylaxis of  Prevention of  Long-term  Prevention of  Prevent stenosis of
venous thrombosis DVT after ABD, prophylaxis of DVT and PE coronary stents
 Preferred drug hip, or knee thrombosis after total hip  Secondary
during pregnancy surgery  Prevention of PE or knee prevention of MI,
 PE and massive  Treatment of associated with  Prevention of ischemic stroke,
DVT DVT with or DVT: stroke in A. and other vascular
 Open heart without a PE  Prevention of Fib events.

, surgery and renal  Prevention of thromboembolis  Prevention of
dialysis ischemic m in prosthetic recurrent DVT
 DIC complications in heart valves and PE
 MI unstable angina,  Prevention of  Treatment of
non-Q wave MI, thrombosis DVT and PE
and STEMI associated with unrelated to
A.Fib orthopedic
 Reduce TIAs and surgery.
recurrent MI

Contraindications  Bleeding risks  Spinal puncture  Use during  Use with other  Active bleeding
 Thrombocytopenia or spinal or pregnancy anticoagulants  Caution with other
 Surgery of eye, epidural  Severe  CrCl < 30 drugs that promote
brain, or spinal anesthesia (severe thrombocytopenia mL/min bleeding
cord neurologic injury)  Uncontrolled  Moderate liver  Must weigh risk
 Lumbar puncture  Severe bleeding impairment vs benefit if using
and regional thrombocytopenia  Lumbar puncture,  Pregnancy with ASA
anesthesia or active bleeding regional  Cautions:
anesthesia,  Renal
surgery of eye, impairment
brain, or spinal delays
cord excretion of
 Bleeding drug
disorders
(hemophilia,
dissecting
aneurysm, GI
ulcer)
 Vitamin K
deficiency, liver
disease,
alcoholism
(disrupt clotting